Abstract

FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline pediatric acute myeloid leukemia therapy. In 12 patients treated at MD Anderson, most achieved remission with good early survival outcomes, and many proceeded to transplant. Common toxicities included cytopenias, comparable to previous regimens.

Subjects:
Myeloid Neoplasia
1.
Umeda
M
,
Ma
J
,
Westover
T
, et al.
A new genomic framework to categorize pediatric acute myeloid leukemia
.
Nat Genet
.
2024
;
56
(
2
):
281
-
293
.
Google Scholar
Crossref
Search ADS
PubMed
 
2.
Shimony
S
,
Stahl
M
,
Stone
RM
.
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management
.
Am J Hematol
.
2023
;
98
(
3
):
502
-
526
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Tomizawa
D
,
Tsujimoto
SI
.
Risk-stratified therapy for pediatric acute myeloid leukemia
.
Cancers (Basel)
.
2023
;
15
(
16
):
4171
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Cooper
TM
,
Alonzo
TA
,
Tasian
SK
, et al.
Children's Oncology Group's 2023 blueprint for research: myeloid neoplasms
.
Pediatr Blood Cancer
.
2023
;
70
(
suppl 6
):
e30584
.
Google Scholar
PubMed
 
5.
El-Cheikh
J
,
Bidaoui
G
,
Saleh
M
,
Moukalled
N
,
Abou Dalle
I
,
Bazarbachi
A
.
Venetoclax: a new partner in the novel treatment era for acute myeloid leukemia and myelodysplastic syndrome
.
Clin Hematol Int
.
2023
;
5
(
2-3
):
143
-
154
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Pollyea
DA
.
Acute myeloid leukemia drug development in the post-venetoclax era
.
Am J Hematol
.
2019
;
94
(
9
):
959
-
962
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
Badawi
M
,
Gopalakrishnan
S
,
Engelhardt
B
, et al.
Dosing of venetoclax in pediatric patients with relapsed acute myeloid leukemia: analysis of developmental pharmacokinetics and exposure-response relationships
.
Clin Ther
.
2024
;
46
(
10
):
759
-
767
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Masetti
R
,
Baccelli
F
,
Leardini
D
,
Locatelli
F
.
Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?
.
Blood Adv
.
2024
;
8
(
13
):
3583
-
3595
.
Google Scholar
Crossref
Search ADS
PubMed
 
9.
Karol
SE
,
Alexander
TB
,
Budhraja
A
, et al.
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study
.
Lancet Oncol
.
2020
;
21
(
4
):
551
-
560
.
Google Scholar
Crossref
Search ADS
PubMed
 
10.
Trabal
A
,
Gibson
A
,
He
J
, et al.
Venetoclax for acute myeloid leukemia in pediatric patients: a Texas Medical Center experience
.
Cancers (Basel)
.
2023
;
15
(
7
):
1983
.
Google Scholar
Crossref
Search ADS
PubMed
 
11.
Baig
MU
,
Rytting
M
,
Roth
M
, et al.
Venetoclax and decitabine in pediatric refractory T-cell lymphoblastic lymphoma
.
J Pediatr Hematol Oncol
.
2021
;
43
(
7
):
e991
-
e996
.
Google Scholar
Crossref
Search ADS
PubMed
 
12.
Gibson
A
,
Dickson
S
,
McCall
D
, et al.
Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia
.
Pediatr Blood Cancer
.
2024
;
71
(
11
):
e31286
.
Google Scholar
Crossref
Search ADS
PubMed
 
13.
DiNardo
CD
,
Lachowiez
CA
,
Takahashi
K
, et al.
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia
.
Am J Hematol
.
2022
;
97
(
8
):
1035
-
1043
.
Google Scholar
Crossref
Search ADS
PubMed
 
14.
DiNardo
CD
,
Lachowiez
CA
,
Takahashi
K
, et al.
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia
.
J Clin Oncol
.
2021
;
39
(
25
):
2768
-
2778
.
Google Scholar
Crossref
Search ADS
PubMed
 
15.
Fleischhack
G
,
Hasan
C
,
Graf
N
,
Mann
G
,
Bode
U
.
IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial
.
Br J Haematol
.
1998
;
102
(
3
):
647
-
655
.
Google Scholar
Crossref
Search ADS
PubMed
 
16.
Hubeek
I
,
Litvinova
E
,
Peters
GJ
, et al.
The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia
.
Int J Oncol
.
2004
;
25
(
6
):
1823
-
1829
.
Google Scholar
PubMed
 
17.
Leonard
JP
,
Martin
P
,
Roboz
GJ
.
Practical implications of the 2016 revision of the World Health Organization classification of lymphoid and myeloid neoplasms and acute leukemia
.
J Clin Oncol
.
2017
;
35
(
23
):
2708
-
2715
.
Google Scholar
Crossref
Search ADS
PubMed
 
18.
Döhner
H
,
Wei
AH
,
Appelbaum
FR
, et al.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
.
Blood
.
2022
;
140
(
12
):
1345
-
1377
.
Google Scholar
Crossref
Search ADS
PubMed
 
19.
Cheson
BD
,
Bennett
JM
,
Kopecky
KJ
, et al.
Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
.
J Clin Oncol
.
2003
;
21
(
24
):
4642
-
4649
.
Google Scholar
Crossref
Search ADS
PubMed
 
20.
Burnett
AK
,
Russell
NH
,
Hills
RK
, et al.
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial
.
J Clin Oncol
.
2013
;
31
(
27
):
3360
-
3368
.
Google Scholar
Crossref
Search ADS
PubMed
 
21.
Pollard
JA
,
Alonzo
TA
,
Gerbing
R
, et al.
Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3/ITD+ acute myeloid leukemia: a report from the Children's Oncology Group protocol AAML1031
.
J Clin Oncol
.
2022
;
40
(
18
):
2023
-
2035
.
Google Scholar
Crossref
Search ADS
PubMed
 
22.
Sung
L
,
Lange
BJ
,
Gerbing
RB
,
Alonzo
TA
,
Feusner
J
.
Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia
.
Blood
.
2007
;
110
(
10
):
3532
-
3539
.
Google Scholar
Crossref
Search ADS
PubMed
 
23.
Xu
Q
,
Li
H
,
Huang
P
, et al.
Investigation of infections status in pediatric patients with acute myeloid leukemia during the induction period-a retrospective study in two medical centers
.
Ann Hematol
.
2024
;
103
(
11
):
4503
-
4510
.
Google Scholar
Crossref
Search ADS
PubMed
 
24.
Paras
G
,
Othus
M
,
Shaw
CM
, et al.
Time to count recovery after post-remission chemotherapy in AML patients [abstract]
.
Blood
.
2022
;
140
(
suppl 1
):
6080
-
6081
.
Google Scholar
 
25.
Rasche
M
,
Zimmermann
M
,
Borschel
L
, et al.
Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012
.
Leukemia
.
2018
;
32
(
10
):
2167
-
2177
.
Google Scholar
Crossref
Search ADS
PubMed
 
26.
Lange
BJ
,
Smith
FO
,
Feusner
J
, et al.
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group
.
Blood
.
2008
;
111
(
3
):
1044
-
1053
.
Google Scholar
Crossref
Search ADS
PubMed
 
© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
Sign in via your Institution